The effect of transplantation of autologous hematopoietic stem cells (AHSCT) in patients with primary biliary cirrhosis (PBC)

Ilyassova B.S., Askarov M.B., Kaliaskarova K.S., Trimova R.S., Gaipov A.

Research output: Contribution to journalArticle

Abstract

Background: PBC is a liver disease in which an immune-mediated injury targets the small intrahepatic bile ducts. It is proposed, the AHSCT influence on the molecules of autoreactivity and then the proinflammatory cells are eliminated. Consequently generation new naïve T-lymphocytes in patients is interrupted, it results to the restoration of the tolerance to autoantigens. The aim of the study: to evaluate of efficiency of AHSCT including to the PBC treatment. Indication: the refractory to the standard therapy. The methods: 10 patients with primary biliary cirrhosis: 4 with the II morphological stage PBC, 2-III stage, 2-IV stage and 2-with overlap syndrome: PBC IIIst + AIH. The AHSCT has realized by 2 stages: 1-aspiration of bone marrow suspension in the amount 200 ml; phenotyping of cells by cell cytometer BD; isolation of the mononuclear fraction and precultivation it during 24-48 h. 2-intravenous transplantation of the cells suspension. The cytokines levels were investigated in the cell supernatant and in the blood serum by ELISA. The results: 7 days after AHSCT the tests have shown the decrease of ALT level from 1.930 ± 0.300, Std. Deviation (SD) 0.949, to 1.466 ± 0.260, SD = 0.821, p = 0.007, of AST level from 1.926 ± 0.415, SD = 1.313 to 1.384 ± 0.207, SD = 0.655, p = 0.005, the total bilirubin level from 60.184 ± 22.539 mkmol/l, SD = 71.275 to 43.619 ± 17.498, SD = 55.334, p = 0.005, the level of direct bilirubin from 44.751 ± 20.605, SD = 65.158, to 20.074 ± 11.447, SD = 36.200, p = 0.007. The parameters of serum protein 69.688 ± 2.457, SD = 7.770, to 77.465 ± 1.172, SD = 3.706, p = 0.005 and serum albumin 39.712 ± 2.853, SD = 9.0197, to 44.088 ± 2.619, SD = 8.282, p = 0.028 increased. Three months later the levels of IL-10, IL-12p70, IL-17, IL-2 and IL-4 didn't change significantly, IFN-γ level was increased (p = 0.005). IL-1b level (p = 0.006) and TNF-α level (p = 0.005) decreased. The SF36 results showed significant improvement. These results have shown the efficiency of AHSCT including to PBC treatment. But clinical trial needs to histological confirming.
Original languageEnglish
Pages (from-to)S14-S15
JournalHepatology International
Volume7
DOIs
Publication statusPublished - 2013

Fingerprint

Biliary Liver Cirrhosis
Hematopoietic Stem Cell Transplantation
Bilirubin
Suspensions
Insemination, Artificial, Homologous
Intrahepatic Bile Ducts
Interleukin-17
Cell Transplantation
Serum Albumin
Interleukin-4
Interleukin-10
Interleukin-2
Liver Diseases
Blood Proteins
Therapeutics
Bone Marrow
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Cytokines
T-Lymphocytes

Keywords

  • Asian
  • T lymphocyte
  • aspiration
  • autoantigen
  • bilirubin
  • bilirubin glucuronide
  • bone marrow
  • clinical trial
  • cytokine
  • enzyme linked immunosorbent assay
  • hematopoietic stem cell
  • human
  • immune mediated injury
  • interleukin 1
  • interleukin 10
  • interleukin 12p70
  • interleukin 2
  • interleukin 4
  • intrahepatic bile duct
  • liver
  • liver disease
  • parameters
  • patient
  • phenotype
  • plasma protein
  • primary biliary cirrhosis
  • serum
  • serum albumin
  • sexually transmitted disease
  • supernatant
  • therapy
  • transplantation

Cite this

The effect of transplantation of autologous hematopoietic stem cells (AHSCT) in patients with primary biliary cirrhosis (PBC). / B.S., Ilyassova; M.B., Askarov; K.S., Kaliaskarova; R.S., Trimova; A., Gaipov.

In: Hepatology International, Vol. 7, 2013, p. S14-S15.

Research output: Contribution to journalArticle

@article{8e22c1a9da82478195ab8b32ed3fae36,
title = "The effect of transplantation of autologous hematopoietic stem cells (AHSCT) in patients with primary biliary cirrhosis (PBC)",
abstract = "Background: PBC is a liver disease in which an immune-mediated injury targets the small intrahepatic bile ducts. It is proposed, the AHSCT influence on the molecules of autoreactivity and then the proinflammatory cells are eliminated. Consequently generation new na{\"i}ve T-lymphocytes in patients is interrupted, it results to the restoration of the tolerance to autoantigens. The aim of the study: to evaluate of efficiency of AHSCT including to the PBC treatment. Indication: the refractory to the standard therapy. The methods: 10 patients with primary biliary cirrhosis: 4 with the II morphological stage PBC, 2-III stage, 2-IV stage and 2-with overlap syndrome: PBC IIIst + AIH. The AHSCT has realized by 2 stages: 1-aspiration of bone marrow suspension in the amount 200 ml; phenotyping of cells by cell cytometer BD; isolation of the mononuclear fraction and precultivation it during 24-48 h. 2-intravenous transplantation of the cells suspension. The cytokines levels were investigated in the cell supernatant and in the blood serum by ELISA. The results: 7 days after AHSCT the tests have shown the decrease of ALT level from 1.930 ± 0.300, Std. Deviation (SD) 0.949, to 1.466 ± 0.260, SD = 0.821, p = 0.007, of AST level from 1.926 ± 0.415, SD = 1.313 to 1.384 ± 0.207, SD = 0.655, p = 0.005, the total bilirubin level from 60.184 ± 22.539 mkmol/l, SD = 71.275 to 43.619 ± 17.498, SD = 55.334, p = 0.005, the level of direct bilirubin from 44.751 ± 20.605, SD = 65.158, to 20.074 ± 11.447, SD = 36.200, p = 0.007. The parameters of serum protein 69.688 ± 2.457, SD = 7.770, to 77.465 ± 1.172, SD = 3.706, p = 0.005 and serum albumin 39.712 ± 2.853, SD = 9.0197, to 44.088 ± 2.619, SD = 8.282, p = 0.028 increased. Three months later the levels of IL-10, IL-12p70, IL-17, IL-2 and IL-4 didn't change significantly, IFN-γ level was increased (p = 0.005). IL-1b level (p = 0.006) and TNF-α level (p = 0.005) decreased. The SF36 results showed significant improvement. These results have shown the efficiency of AHSCT including to PBC treatment. But clinical trial needs to histological confirming.",
keywords = "Asian, T lymphocyte, aspiration, autoantigen, bilirubin, bilirubin glucuronide, bone marrow, clinical trial, cytokine, enzyme linked immunosorbent assay, hematopoietic stem cell, human, immune mediated injury, interleukin 1, interleukin 10, interleukin 12p70, interleukin 2, interleukin 4, intrahepatic bile duct, liver, liver disease, parameters, patient, phenotype, plasma protein, primary biliary cirrhosis, serum, serum albumin, sexually transmitted disease, supernatant, therapy, transplantation",
author = "Ilyassova B.S. and Askarov M.B. and Kaliaskarova K.S. and Trimova R.S. and Gaipov A.",
year = "2013",
doi = "10.1007/s12072-013-9429-0",
language = "English",
volume = "7",
pages = "S14--S15",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",

}

TY - JOUR

T1 - The effect of transplantation of autologous hematopoietic stem cells (AHSCT) in patients with primary biliary cirrhosis (PBC)

AU - B.S., Ilyassova

AU - M.B., Askarov

AU - K.S., Kaliaskarova

AU - R.S., Trimova

AU - A., Gaipov

PY - 2013

Y1 - 2013

N2 - Background: PBC is a liver disease in which an immune-mediated injury targets the small intrahepatic bile ducts. It is proposed, the AHSCT influence on the molecules of autoreactivity and then the proinflammatory cells are eliminated. Consequently generation new naïve T-lymphocytes in patients is interrupted, it results to the restoration of the tolerance to autoantigens. The aim of the study: to evaluate of efficiency of AHSCT including to the PBC treatment. Indication: the refractory to the standard therapy. The methods: 10 patients with primary biliary cirrhosis: 4 with the II morphological stage PBC, 2-III stage, 2-IV stage and 2-with overlap syndrome: PBC IIIst + AIH. The AHSCT has realized by 2 stages: 1-aspiration of bone marrow suspension in the amount 200 ml; phenotyping of cells by cell cytometer BD; isolation of the mononuclear fraction and precultivation it during 24-48 h. 2-intravenous transplantation of the cells suspension. The cytokines levels were investigated in the cell supernatant and in the blood serum by ELISA. The results: 7 days after AHSCT the tests have shown the decrease of ALT level from 1.930 ± 0.300, Std. Deviation (SD) 0.949, to 1.466 ± 0.260, SD = 0.821, p = 0.007, of AST level from 1.926 ± 0.415, SD = 1.313 to 1.384 ± 0.207, SD = 0.655, p = 0.005, the total bilirubin level from 60.184 ± 22.539 mkmol/l, SD = 71.275 to 43.619 ± 17.498, SD = 55.334, p = 0.005, the level of direct bilirubin from 44.751 ± 20.605, SD = 65.158, to 20.074 ± 11.447, SD = 36.200, p = 0.007. The parameters of serum protein 69.688 ± 2.457, SD = 7.770, to 77.465 ± 1.172, SD = 3.706, p = 0.005 and serum albumin 39.712 ± 2.853, SD = 9.0197, to 44.088 ± 2.619, SD = 8.282, p = 0.028 increased. Three months later the levels of IL-10, IL-12p70, IL-17, IL-2 and IL-4 didn't change significantly, IFN-γ level was increased (p = 0.005). IL-1b level (p = 0.006) and TNF-α level (p = 0.005) decreased. The SF36 results showed significant improvement. These results have shown the efficiency of AHSCT including to PBC treatment. But clinical trial needs to histological confirming.

AB - Background: PBC is a liver disease in which an immune-mediated injury targets the small intrahepatic bile ducts. It is proposed, the AHSCT influence on the molecules of autoreactivity and then the proinflammatory cells are eliminated. Consequently generation new naïve T-lymphocytes in patients is interrupted, it results to the restoration of the tolerance to autoantigens. The aim of the study: to evaluate of efficiency of AHSCT including to the PBC treatment. Indication: the refractory to the standard therapy. The methods: 10 patients with primary biliary cirrhosis: 4 with the II morphological stage PBC, 2-III stage, 2-IV stage and 2-with overlap syndrome: PBC IIIst + AIH. The AHSCT has realized by 2 stages: 1-aspiration of bone marrow suspension in the amount 200 ml; phenotyping of cells by cell cytometer BD; isolation of the mononuclear fraction and precultivation it during 24-48 h. 2-intravenous transplantation of the cells suspension. The cytokines levels were investigated in the cell supernatant and in the blood serum by ELISA. The results: 7 days after AHSCT the tests have shown the decrease of ALT level from 1.930 ± 0.300, Std. Deviation (SD) 0.949, to 1.466 ± 0.260, SD = 0.821, p = 0.007, of AST level from 1.926 ± 0.415, SD = 1.313 to 1.384 ± 0.207, SD = 0.655, p = 0.005, the total bilirubin level from 60.184 ± 22.539 mkmol/l, SD = 71.275 to 43.619 ± 17.498, SD = 55.334, p = 0.005, the level of direct bilirubin from 44.751 ± 20.605, SD = 65.158, to 20.074 ± 11.447, SD = 36.200, p = 0.007. The parameters of serum protein 69.688 ± 2.457, SD = 7.770, to 77.465 ± 1.172, SD = 3.706, p = 0.005 and serum albumin 39.712 ± 2.853, SD = 9.0197, to 44.088 ± 2.619, SD = 8.282, p = 0.028 increased. Three months later the levels of IL-10, IL-12p70, IL-17, IL-2 and IL-4 didn't change significantly, IFN-γ level was increased (p = 0.005). IL-1b level (p = 0.006) and TNF-α level (p = 0.005) decreased. The SF36 results showed significant improvement. These results have shown the efficiency of AHSCT including to PBC treatment. But clinical trial needs to histological confirming.

KW - Asian

KW - T lymphocyte

KW - aspiration

KW - autoantigen

KW - bilirubin

KW - bilirubin glucuronide

KW - bone marrow

KW - clinical trial

KW - cytokine

KW - enzyme linked immunosorbent assay

KW - hematopoietic stem cell

KW - human

KW - immune mediated injury

KW - interleukin 1

KW - interleukin 10

KW - interleukin 12p70

KW - interleukin 2

KW - interleukin 4

KW - intrahepatic bile duct

KW - liver

KW - liver disease

KW - parameters

KW - patient

KW - phenotype

KW - plasma protein

KW - primary biliary cirrhosis

KW - serum

KW - serum albumin

KW - sexually transmitted disease

KW - supernatant

KW - therapy

KW - transplantation

UR - http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L71307470 http://dx.doi.org/10.1007/s12072-013-9429-0

UR - http://www.mendeley.com/research/effect-transplantation-autologous-hematopoietic-stem-cells-ahsct-patients-primary-biliary-cirrhosis

U2 - 10.1007/s12072-013-9429-0

DO - 10.1007/s12072-013-9429-0

M3 - Article

VL - 7

SP - S14-S15

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

ER -